175 related articles for article (PubMed ID: 30810585)
1. Why are biosimilars much more complex than generics?
Pagani E
Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
[No Abstract] [Full Text] [Related]
2. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
Oza B; Radhakrishna S; Pipalava P; Jose V
J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
[TBL] [Abstract][Full Text] [Related]
4. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
Wright EE; Blevins TC; Reed B; Pollom RD
J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
[TBL] [Abstract][Full Text] [Related]
5. Fractal geometry as a new approach for proving nanosimilarity: a reflection note.
Demetzos C; Pippa N
Int J Pharm; 2015 Apr; 483(1-2):1-5. PubMed ID: 25659328
[TBL] [Abstract][Full Text] [Related]
6. BIOSIMILAR DRUGS ARE NOT GENERICS.
Zangeneh F; Dolinar R
Endocr Pract; 2016 Jan; 22(1):6-7. PubMed ID: 26731083
[No Abstract] [Full Text] [Related]
7. On safety margin for drug interchangeability.
Zheng J; Chow SC; Song F
J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
[TBL] [Abstract][Full Text] [Related]
8. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.
Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
Br J Ophthalmol; 2020 Jan; 104(1):2-7. PubMed ID: 31315829
[TBL] [Abstract][Full Text] [Related]
9. What are biosimilars and are they important?
Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
Dranitsaris G; Amir E; Dorward K
Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Overview on Biosimilars.
Kadam V; Bagde S; Karpe M; Kadam V
Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
[TBL] [Abstract][Full Text] [Related]
13. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
Rasmussen JT; Ipema HJ
Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar insulins: a European perspective.
DeVries JH; Gough SC; Kiljanski J; Heinemann L
Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
[TBL] [Abstract][Full Text] [Related]
15. Insights of biosimilars through SWOT analysis.
Patel MM; Shah PJ; Patel BM
Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
[No Abstract] [Full Text] [Related]
16. [Biosimilars : Current state of the build up to series production].
Aringer M; Dörner T
Z Rheumatol; 2013 Nov; 72(9):873-7. PubMed ID: 23934050
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
18. The Challenging Future of the Biosimilars Market.
Joseph E
J Pharm Pract; 2016 Jun; 29(3):266-7. PubMed ID: 27169735
[No Abstract] [Full Text] [Related]
19. Biosimilar drugs : concerns and opportunities.
Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
[TBL] [Abstract][Full Text] [Related]
20. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
Warren JB
Br J Clin Pharmacol; 2013 Jan; 75(1):7-14. PubMed ID: 22574725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
